Quick Answer
CATALYST PHARMACEUTICALS, INC. reported Operating Income Loss of $257.78 million for the year ending 2025.
- CATALYST PHARMACEUTICALS, INC. showed an increase of +32.1% in Operating Income Loss from 2024 to 2025.
- This data is from CATALYST PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), CATALYST PHARMACEUTICALS, INC.'s Operating Income Loss has grown by 3,643.1%.
- Historical annual values: Fiscal year 2025: $257.78 million | Fiscal year 2024: $195.12 million | Fiscal year 2023: $86.81 million | Fiscal year 2022: $101.84 million | Fiscal year 2021: $52.39 million | Fiscal year 2020: $41.30 million | Fiscal year 2019: $31.82 million | Fiscal year 2018: -$35.30 million | Fiscal year 2017: -$18.68 million | Fiscal year 2016: -$19.28 million | Fiscal year 2015: -$20.40 million | Fiscal year 2014: -$14.59 million | Fiscal year 2013: -$10.31 million | Fiscal year 2012: -$5.22 million | Fiscal year 2011: -$6.08 million | Fiscal year 2010: -$4.02 million | Fiscal year 2009: -$7.28 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: